Antinociceptive Activity of Borreria verticillata: In vivo and In silico Studies

Borreria verticillata (L.) G. Mey. known vassourinha has antibacterial, antimalarial, hepatoprotective, antioxidative, analgesic, and anti-inflammatory, however, its antinociceptive action requires further studies. Aim of the study evaluated the antinociceptive activity of B. verticillata hydroalcoholic extract (EHBv) and ethyl acetate fraction (FAc) by in vivo and in silico studies. In vivo assessment included the paw edema test, writhing test, formalin test and tail flick test. Wistar rats and Swiss mice were divided into 6 groups and given the following treatments oral: 0.9% NaCl control group (CTRL), 10 mg/kg memantine (MEM), 10 mg/kg indomethacin (INDO), 500 mg/kg EHBv (EHBv 500), 25 mg/kg FAc (FAc 25) and 50 mg/kg FAc (FAc 50). EHBv, FAc 25 and 50 treatments exhibited anti-edematous and peripheral antinociceptive effects. For in silico assessment, compounds identified in FAc were subjected to molecular docking with COX-2, GluN1a and GluN2B. Ursolic acid (UA) was the compound with best affinity parameters (binding energy and inhibition constant) for COX-2, GluN1a, GluN2B, and was selected for further analysis with molecular dynamics (MD) simulations. In MD simulations, UA exhibited highly frequent interactions with residues Arg120 and Glu524 in the COX-2 active site and NMDA, whereby it might prevent COX-2 and NMDA receptor activation. Treatment with UA 10 mg/Kg showed peripheral and central antinociceptive effect. The antinociceptive effect of B. verticillata might be predominantly attributed to peripheral actions, including the participation of anti-inflammatory components. Ursolic acid is the main active component and seems to be a promising source of COX-2 inhibitors and NMDA receptor antagonists.


INTRODUCTION
Pain is a warning system that informs the body about the occurrence of tissue damage (Nickel et al., 2012). In the pathophysiology of pain several biological actions are involved, including activation of cyclooxygenase 2 enzyme (COX-2) and N-methyl-D-aspartate (NMDA) receptor.
COX-2 is upregulated in the central nervous system in response to inflammatory factors. It is a rate-limiting enzyme for prostanoid production during inflammation (Ricciotti and Fitzgerald, 2011). Prostaglandin E2, the main pro-inflammatory prostanoid, induces painful hypersensitivity through modulation in the nociceptive pathways, activates the periphery ionic channels such as sodium, calcium, and potentiates the central activation of NMDA and α-amino-3hydroxy-5-methylsoxazol-4-propionic (AMPA) receptors (Chen et al., 2013). Inhibition of COX-2 enzymatic activity prevents prostanoid production, thus this enzyme is a usual target of non-steroidal anti-inflammatory drugs (NSAIDs) (Zaiss et al., 2014).
The activation of NMDA receptor requires the binding of glycine and glutamate to its subunits GluN1 and GluN2, respectively (Tajima et al., 2016). It is well-known that activation of NMDA receptors causes central sensitization, amplification of spinal nociception, increased ionic conductance and membrane depolarization (Phang and Tan, 2013). For this reason, NMDA receptor antagonists (e.g., memantine) are considered an option in the management of opioid-resistant and chronic pain (Hewitt, 2000).
Therefore, NSAIDs and NMDA receptor antagonists are used to afford pain relief. However, the use of these agents is limited by the occurrence of side effects, such as dizziness, vomiting, constipation, and gastric erosions. These problems and the impact of pain in the quality of life of patients evidence the need of novel therapeutic targets for pain management.
New technologies have been applied to the assessment of the pharmacological properties of extracts and active principles of medicinal plants, such as molecular docking and molecular dynamic, which is a computer-based approach used to give a prediction of the ligand-receptor complex structure (Meng et al., 2011). The combination of computational technique with biological assay became an important strategy toward finding plant-based drugs (Sharma and Sarkar, 2012).
Considering the factors that contribute to the mechanisms of pain and the use of medicinal plants as multi-targets therapeutic alternatives, the aim of the present study was to assess the antinociceptive activity of the crude hydroalcoholic extract and ethyl acetate fraction of B. verticillata. Furthermore, evaluate the molecular interactions of compounds present in ethyl acetate fraction with COX-2 enzyme and NMDA receptor.

Obtaining the Hydroalcoholic Extract and the Ethyl Acetate Fraction
Aerial parts of B. verticillata were dried at 38 • C in an oven with circulating air and powdered with a knife mill to obtain a moderately coarse powder (particle sizes under 710 µm and over 250 µm). The powder of B. verticillata aerial parts was macerated with 70% ethanol for 5 days (this step was repeated 3 times) obtaining a solution. The solution was filtered and concentrated to a small volume at 40 • C in a rotary evaporator under vacuum, to obtain the hydroalcoholic extract of B. verticillata (EHBv). EHBv was dissolved in methanol:water (70:30,v/v) for 60 min under mechanical agitation, and successively subjected to liquid-liquid extraction with hexane, chloroform, and ethyl acetate. The solutions were filtered and concentrated at 40 • C in a rotary evaporator under vacuum, to ethyl acetate fraction (FAc).

Phenolic and Flavonoid Content Assessment
Total phenolic content (TPC) was determined using Folin-Ciocalteu reagent and 20% sodium carbonate. The reaction was kept in the dark for 2 h at room temperature; absorbance was read with a spectrophotometer at 760 nm (Dutra et al., 2014). The PCC was calculated based on the calibration curve plotted with gallic acid standard solutions (1.0-30.0 µg/mL) and is expressed as gallic acid equivalent (mg/mL).
Total flavonoid content (TFC) was determined using a 5% methanol solution of aluminum chloride (AlCl 3 ). The reaction was kept in the dark for 30 min at room temperature; absorbance was read with a spectrophotometer at 425 nm (Dutra et al., 2008). The TFC was calculated based on the calibration curve plotted with quercetin standard solutions (1.0-30.0 µg/mL) and is expressed as quercetin equivalent (mg/mL).

Gas Chromatography-Mass Spectrometry (GC-MS)
FAc (10 mg) was derivatized in pyridine (300 µL) and bis-(trimethylsilyl) trifluoroacetamide with trimethylchlorosilane (BSTFA/TMCS, 100 µL) and was heated at 80 • C for 1 h. The derivatized product was analyzed with a gas chromatograph (GC-2010, Shimadzu, Japan) coupled to a mass spectrometer (GCMS-QP2010 SE, Shimadzu, Japan) with an Rtx-5MS column (30 m × 0.25 mm ix 0.25 µm, Restek, USA), helium as the carrier gas and a 1.0 mL/min flow rate. The oven temperature was first kept at 70 • C and then set to increase 4 • C/min until 310 • C. The temperature was maintained at 310 • C for 4 min. The injector temperature was set to 250 • C; the injection volume was 1.0 mL at a 1:30 ratio. The mass spectra were obtained by means of electron impact ionization (70 eV) on total ion scanning mode (40 to 1,000 m/z) with the ion source at 200 • C. The compounds were identified through comparison of the obtained mass spectra with the NIST 11 library.

Animals
The present study used adult, male and female Wistar Rattus norvegicus rats with weights ranging from 200 to 300 g and adult, male, and female Mus musculus mice with weights ranging from 25 to 35 g, which were procured from the Central Vivarium (Biotério Central), Federal University of Maranhão (UFMA). Animals were provided with free access to food and water in an environment with controlled temperature and 12/12 h light/dark cycle. This study was carried out in accordance with the recommendations of IASP Guidelines for the Use of Animals in Research. The experimental protocols were approved by the UFMA Ethics in Animal Use Committee (CEUA), ruling no. 17, protocol no. 23115.013545/2015-89.

Experimental Groups
Six experimental groups with 6 animals each were used. CTRL group was treated oral (p.o) with 0.9% NaCl (0.1 mL/kg); the INDO group was treated with indomethacin (10 mg/kg p.o.); MEM group was treated with memantine (10 mg/kg p.o.); FAc groups were treated with fraction the B. verticillata at doses of 25 mg/kg p.o (FAc 25) and 50 mg/kg p.o (FAc 50) and the EHBv group was treated with the hydroalcoholic extract of B. verticillata (500 mg/kg p.o.). NaCl 0.9% was used as the vehicle to dissolve the solutions.
After the results obtained in the in silico studies, it was observed that of the active compounds ursolic acid (UA) present in the FAc presented better results. Then 6 animals were treated orally with UA (10 mg/kg p.o) and submitted to the carrageenaninduced paw edema test and tail flick.

Carrageenan-Induced Paw Edema
This test was performed to assess the pharmacological activities of the investigated compounds after subplantar injection of carrageenan. Mice were distributed and treated as described in the "Experimental groups" section. Sixty minutes after the onset of treatments, paw edema was induced through administration of 50 µL of 1% carrageenan via subplantar injection in the right paw; the same volume of 0.9% NaCl was injected in the left paw. The paw volume was measured with a digital plethysmometer 1, 2, 3, 4, and 5 h after induction. Edema was calculated as the difference between the right and left paw volume and is expressed as paw volume variation (ml) over time (Winter et al., 1962;Sadeghi et al., 2011).

Writhing Test
The acetic acid-induced writhing test is described as a visceralsomatic inflammatory model used for pharmacological screening of central and peripheral antinociceptive activity. Mice were distributed and treated as described in the "Experimental groups" section. Sixty minutes after treatment onset, abdominal writhing was induced through intraperitoneal administration of 0.8% acetic acid (10 mL/kg). The number of contractions was cumulatively counted for 20 min after induction (Koster et al., 1959). The results are expressed as the average number of cumulative abdominal contractions (Shamsi and Keyhanfar, 2013;Mansouri et al., 2014).

Formalin Test
The formalin test for nociception allows assessment of the neurogenic nociceptive mechanisms triggered by activation of nociceptive fibers and the inflammatory mechanisms activated following the release of inflammatory mediators. Mice were treated as described above; 60 min later, a subplantar injection of 20 µL of 2.5% formalin was administered in the right paw. The nociceptive response, characterized by paw licking or biting, was observed during the first 5 min to assess neurogenic mechanisms and then from minutes 15 to 30 to assess inflammatory mechanisms (Hunskaar and Hole, 1987;Nemoto et al., 2015).

Tail Flick Test
This test was performed to assess central antinociceptive activity through the stimulation of spinal reflexes. Rats were treated as described above; 60 min later, a thermal stimulus was applied to the final third of the tail (Ugo Basile, Varese-Italy), and the latency to tail flick was measured at baseline, 30, 60, 120, and 180 min. The stimulus intensity was set to obtain 3-6 s latency times; the cutoff point was set to 10 s to avoid tail injury (D' Amour and Smith, 1941;Mansouri et al., 2014).

Structure of Compounds and Receptors
The compounds identified in FAc were obtained from the PubChem Project database and were structurally plotted in 3 dimensions (3D) using GaussView 5.0.8 (Dennington et al., 2009). Geometric and vibrational properties were calculated (optimized) under vacuum by means of the density functional theory (DFT) method using functional hybrid B3LYP combined with basis 6-31 ++ G (d, p) in the Gaussian 09 program (Frisch et al., 2009).
The 3D structure of Swiss mouse COX-2 (chain A) was obtained from the Protein Data Bank (PDB, #1DDX). The 3D structures of the drugs MEM and INDO were obtained from the PubChem Project (CID 4054 and 3715, respectively).
The structural model of the Rattus norvegicus NMDA receptor subunits GluN1a and GluN2B was obtained by means of homology modeling.

Homology Modeling
Homology modeling was performed following Ramos et al. (2012) with MODELER 9v14 (Webb and Sali, 2014) and the amino acid sequences of subunits GluN1a and GluN2B (NCBI GI 645985944 and GI 645985945, respectively). As the crystallographic structure of the PDB NMDA (code 4PE5) are not complete, models were generated by homology modeling (HM-GluN1a and HM-GluN2B) using the crystallographic structure of PDB code 4TLL (GluN1/GluN2B NMDA) as template. The quality of the selected models was checked with the programs ProCheck (Laskowski et al., 1993) and Errat (Colovos and Yeates, 1993), run in the SAVES server with Z-Score (ProSA-web Protein Structure Analysis) (Table S2).

Molecular Docking
The AutoDock 4.2 package (Morris et al., 2008) was used to prepare proteins (refined models) and ligands for docking calculations using the AutoDock Tools (ADT) module, version 1.5.6, according to Ramos et al. (2012). The affinity grid centers were defined on residue Arg120 for COX-2, Tyr513 for NMDA GluN1A and Arg487 for NMDA GluN2B. The initial complex coordinates for MD simulations were selected based on the lowest energy configuration of clusters combined with visual inspection.

Molecular Dynamics of Complexes
The MD simulations of the complexes selected after molecular docking were performed using GROMACS 4.6.7 software (Berk et al., 2014) following Ramos et al. (2012). The ligand topologies were generated with Automated Topology Builder (ATB) and Repository version 2.1 (Malde et al., 2011). The protonation states of histidine residues were determined using the H++ online server-http://biophysics.cs.vt.edu/hppdetails. php. To enlarge the sample, 3 10-ns MD simulations were performed per complex using different atomic velocities assigned according to the Maxwell distribution. The data generated for the last 4 ns in each simulated system were used for analysis. During the production step, 123 frames were obtained at 100ps intervals. The details of the interactions were calculated with LigPlot++ software (Laskowski et al., 1993). A minimum of 50% of contact (total of hydrophobic interactions and hydrogen bonds) in the analyzed frames was defined as a criterion of binding efficacy.

Statistical Analysis
Mean values among experimental groups were compared through univariate analysis of variance (one-way ANOVA) followed by the Newman-Keuls test at p < 0.05. The data were analyzed in the terms of means ± standard errors using GraphPad Prism 5 software.

Phenolic and Flavonoid Content Assessment
The concentrations of total phenolic compounds and flavonoids in EHBv were 9.61 and 7.67 mg/mL, respectively.

Carrageenan-Induced Paw Edema Test
Subplantar injection of carrageenan induced edema on the animals' paws that lasted the full period of observation, i.e., 5 h, with the peak of edema starting 4 h after induction.
Treatments consisting of EHBv 500 and FAc (FAc 25 and FAc 50) significantly reduced carrageenan-induced edema at 3, 4, and 5 h after induction compared to control. The percentage of reduction in edema caused by the treatment was 41, 42, and 43% for EHBv 500; 48, 61, and 67% for FAc 25; and 41, 53, and 61% for FAc 50 respectively. Treatment with INDO significantly reduced edema by 72, 74, and 77%, while MEM reduced edema by 20, 18, and 14% at 3, 4, and 5 h after induction, respectively, compared to control. Comparisons between the effects of B. verticillata extract, fractions and standard drugs (indomethacin and memantine) revealed that INDO, FAc 25, and FAc 50 were the most efficacious in reducing edema. The effects of FAc at doses of 25 and 50 mg/kg were equivalent, without statistically significant difference (Figure 1 and Table S1).

Writhing Test
Intraperitoneal administration of acetic acid caused pain to animals during entire 20 min of assessment. Treatments with EHBv 500, FAc 25, and FAc 50 significantly reduced the number of abdominal contractions by 71, 72, and 42%, respectively, compared to control (Figure 2) (Figure 3). The effects of EHBv 500, FAc 25 and FAc 50 were similar to MEM and INDO treatments, without statistically significant differences.

Tail Flick Test
Treatment with MEM significantly reduced pain, as evidenced by 15, 40, and 40% increases in the latency time at 60, 120, and 180 min, respectively, compared to control. INDO, EHBv 500, FAc 25, and FAc 50 were unable to increase the latency time of the animals during the 180 min assessment period (Figure 4).

Molecular Docking
All compounds identified in FAc on HPLC UV-Vis analysis were selected for molecular docking. The parameters affinity (binding energy [ G bind ] and inhibition constant [Ki]) and values of all ligands are described in Table 3.
The interactions of UA, MEM, and INDO with amino acids identified in selected configurations obtained through molecular docking calculations are described in Table 4.

Molecular Dynamics Simulations
The lowest docking-energy conformation of the cluster with lowest energy was chosen as initial structure for the molecular dynamics simulations of the COX-2 (Figures 5A-C) GluN1a ( Figure 6A and Figure S3) and GluN2B (Figure 6B and Figure  S4) (UA, INDO or MEM) complexes. Interactions ≥50% were considered to be relevant.
( Figure 8D), MEM exhibited 50% interaction with Glu489 (30% of hydrophobic interactions and 20% of hydrogen bonds). The frequencies of interaction of UA and MEM with GluN1a and GluN2B are described in Figure 8.

Test In vivo of In silico Selected Compound
After analysis of the results obtained from the in silico tests, tests of Carrageenan-induced paw edema and Tail flick with UA (Sigma-Alderich) were performed.
Treatment with UA (10 mg/kg) significantly reduced carrageenan-induced edema by at 5 h analyzed. These reductions were 57-84% when compared to the control group. Comparisons of the effects UA, INDO, and MEM revealed that UA were most efficacious in reducing edema. Treatment with INDO and of MEM reduced significantly the paw edema in the 3, 4, and 5 h when compared with CTRL. These reductions were similar to those mentioned above (Figure 9).
In tail flick test, treatment with UA (10 mg/kg) significantly increased the animal latency time at 30-120 min at 28-42% when compared to control. This effect was not observed after 180 min. Treatment with MEM significantly increased latency time when compared to control. These results were similar to those mentioned above (Figure 10).

DISCUSSION
The assays performed in the present study showed that B. verticillata had peripheral antinociceptive effects and antiinflammatory properties. The in silico tests indicated that UA was chief among the active components identified in FAc, exhibiting relevant interactions with amino-acid residues in COX-2 and NMDA receptor active sites.
The FAc doses (25 and 50 mg/kg) used in this study were chosen according to results obtained in previous studies developed by our research group. Our preliminary studies with EHBv demonstrated that doses 250 and 500 mg/kg had an antinociceptive effect. In order to define the doses used in FAc, we reduced the EHBv dose by 100 times, resulting in doses of 25 and 50 mg/kg.
The anti-edematous effects of EHBv 500, FAc 25, and FAc 50 were similar to INDO starting 3 h after induction. Studies have shown that the paw edema test has a maximum parameter in 3-4 h lasting up to 5 h. After this period of time, induction loses its effectiveness and due to this reason we do not continue the evaluation (Eisenberg et al., 1994;Castardo et al., 2008). Paw edema characteristically develops in 2 stages: the first stage begins with carrageenan administration and lasts up to 2 h, corresponding to the exudative phase of inflammation, which is triggered by the release of inflammatory mediators such as histamine, serotonin and bradykinin. The second stage begins 3 h after carrageenan administration and is characterized by neutrophil infiltration and is sustained by prostanoids (Wilches et al., 2015;Honmore et al., 2016). Along the inflammatory process, or when tissue damage occurs, several substances are released that promote vasodilation, plasma extravasation and cell recruitment. In addition, glutamate release by primary afferent fibers (class Aδ and C) is increased, as is the activation of glutamatergic receptors, such as NMDA, with consequent propagation of action potentials and the release of excitatory neurotransmitters in the posterior horn of the spinal cord (Miller et al., 2011). Accordingly, the anti-edematous effect of B. verticillata FAc might be attributed to COX-2 inhibition and the consequent reduction of PGE 2 synthesis, as it also occurs in the case of oral treatment with INDO. In addition, previous studies showed that blockade of the NMDA receptor also influences inflammation, as it reduces leukocyte migration (Bong et al., 1996) proinflammatory cytokine induction (Morel et al., 2013) and partially inhibits enzyme phospholipase A 2 (Buritova et al., 1996); all of which explain the anti-edematous effect of MEM.
The EHBv 500, FAc 25, and FAc 50 treatments reduced the number of abdominal contractions on the writhing test by 71, 72, and 42%, respectively. The effects of EHBv 500 and FAc 25 were equivalent to INDO and the effect of FAc 50 was equivalent to MEM.
The writhing test is a visceral inflammatory pain model used for screening compounds with peripheral analgesic activity; it involves activation of somatic and visceral receptors in addition to induction of local inflammation mediated by prostaglandins, bradykinin, tumor necrosis factor (TNF) α and interleukins (ILs) 1β and 8 (Rodrigues et al., 2012;Olonode et al., 2015). Some studies have demonstrated increased activation of peripheral receptors and elevated spinal cord glutamate concentrations in inflammatory pain models (Santos et al., 2005;Shamsi and Keyhanfar, 2013). As the effects of EHBv 500 and FAc 50 treatments were equivalent to INDO, the results of the present study might be mainly attributed to COX-2 inhibition and the consequent reduction of PGE 2 synthesis. In addition, we must also bear in mind the peripheral inhibition of the action of glutamate on nociceptors induced by MEM, as the effects of this drug and FAc 50 were equivalent.
The results of the present study showed that oral treatment with MEM, FAc 25, and FAc 50 reduced the nociceptive response in both phases of the formalin test. Treatments with EHBv and INDO reduced the nociceptive response time only in the inflammatory phase. The reductions in the nociceptive response induced by B. verticillata extract and FAc were similar to MEM and INDO in the first and second phases of formalin test, respectively.
The formalin-induced nociception model involves a biphasic nociceptive response. The first phase (0-5 min) is neurogenic, when class C fibers are predominantly activated; the second phase (15-30 min) corresponds to inflammation and depends on a combination of inflammatory mediators and peripheral and central sensitization (Hunskaar and Hole, 1987;Tjolsen et al., 1992;Liberato et al., 2003).
Peripheral NMDA receptors contribute to the triggering and maintenance of peripheral sensitization under conditions characterized by cell damage and inflammation (Christoph et al., 2005). Several studies have shown that NMDA antagonists, such as MEM, are able to reduce the nociceptive response during both the first and second phases (Davidson and Carlton, 1998;Liberato et al., 2003). McRoberts et al. (2011) found a 50% reduction of the inflammatory phase in GluN1-knockout rats, which suggests that reduced expression of the NMDA receptor decreases glutamateand substance-P-mediated synaptic signaling in the spinal cord.
NSAIDs such as INDO decrease nociception in the second phase of the nociceptive response only (Tjolsen et al., 1992). On those grounds, one might attribute the reduction of nociception in the first phase to the inhibition of the peripheral action of glutamate on nociceptors and, in the second phase, inhibition of COX-2 and PGE 2 synthesis.
The tail flick test was performed in the present study to investigate the central analgesic potential of EHBv and FAc. The EHBv 500, FAc 25, FAc 50, and INDO treatments were not able to promote central analgesia. In turn, the latency periods were longer (60, 120, and 180 min after treatment, respectively) than with 10 mg/kg MEM. According to Danneman et al. (1994), the tail behavioral response to nociceptive stimuli is predominantly regulated by spinal and supraspinal structures. Thus, the analgesic effect of MEM is due to the blockade of the NMDA receptor, with consequent reduction of central sensitization mediated by excitatory neurotransmitters, such as glutamate (Parsons et al., 1999;Morel et al., 2013).
The absence of the dose-dependent effect can be explained by reducing the dissolution of the higher dose and the fact that probably the largest dose does not have the same amounts of active compounds present at the lowest dose.
On the basis of in vivo tests results, a peripheral antinociceptive activity of B. verticillata can be attributed to a reduction in the activity of COX-2 and the peripheral NMDA receptor. In addition the peripheral antinociceptive activity of B. verticillata detected in the present study agrees with the findings described by Abdullahi-Gero et al. (2014b). In that study, oral and intraperitoneal treatments with the ethanolic extract of B. verticillata leaves in doses of 200-1,000 mg/kg exhibited peripheral and central analgesic and anti-inflammatory effects; furthermore, the results suggested that the 50% lethal dose (LD 50 ) for mice and rats is ≥5,000 mg/kg.
According to the chemical analysis results, the biological activity of B. verticillata might be mainly attributed to phenolic compounds and triterpenes, since constituents of these metabolite classes were identified in EHBv and FAc. Some studies showed that these compounds have anti-inflammatory and analgesic effects, as follows: gallic acid-reductions in allodynia and anti-inflammatory effects (Angélica et al., 2013); caffeic acid-reductions in leukocyte migration and free radical and nitric oxide production (Mehrotra et al., 2011); ellagic acid-interaction with opioid receptors (Mansouri et al., 2014) and UA-inhibition of nuclear factor-kappa B (NF-kB) activity (Takada et al., 2010).
In order to determine the mechanisms and possible multitargets of the peripheral antinociceptive activity of B. verticillata, the compounds identified in the FAc were submitted to in silico studies. Gallic acid, caffeic acid, ellagic acid, and UA were subjected to molecular docking analysis, targeting COX-2, and NMDA receptor.
According to Guimarães et al. (2014), negative G bind values represent favorable interactions of the ligand-receptor complex. The molecular docking interactions in Table 3 demonstrated that UA had lower binding energies with the NMDA receptor subunits GluN1a (−7.02 kcal/mol), GluN2B (−5.69 kcal/mol) and COX-2 (−9.89 kcal/mol). Therefore, the UA was the ligand that presented better interactions with the NMDA receptor and COX-2, hence it was selected for MD simulations and in vivo tests.
UA interacted with COX-2 and both NMDA receptor subunits as well as the standard drugs INDO and MEM. From a structural point of view, the COX-2 active site consists of a lipophilic channel with a gate formed by residues Arg120, Tyr355, and Glu524 (Rowlinson et al., 2003), and its activation leads to metabolic changes in arachidonic acid (AA) based on interactions with COX-2 residues Arg120, Tyr355, Tyr385, and Ser530, resulting in prostaglandin production (Xu et al., 2014).
Several studies have confirmed the relevance of interactions involving the aforementioned amino acids, thus pointing to them as potential targets in the investigation of COX-2 inhibitors. Fenamic acid derivatives were assessed for COX-2 inhibitory actions in vitro; once the efficacy of the compounds was established, the complexes were subjected to x-ray crystallography. The results indicated interactions of fenamic acid derivatives with Arg120, Tyr355, Tyr385, Trp387, Glu524, and Leu531 (Orlando and Malkowski, 2016). In vitro  evaluation of the COX-2 inhibitory potential of meloxicam and isoxicam followed by x-ray crystallography detected interactions of both compounds with Met113, Leu117, Arg120, Ile345, Val349, Leu352, Leu359, Phe518, Ala527, Ser530, and Leu531 (Xu et al., 2014). The interaction of COX-2 with ibuprofen, another NSAID with anti-inflammatory and analgesic activities, involved the participation of COX-2 residues Arg120, Val349, Tyr355, Trp387, Met522, Val523, Gly526, Ala527, and Ser530 (Orlando et al., 2015). The results of that study further showed that residues Arg120 and Tyr355, located in the COX-2 channel gate, are crucial for the enzyme's interaction with ibuprofen.
isoxicam and ibuprofen interactions), and Glu524 (close to Val523, involved in meloxicam and ibuprofen interactions, and to Gly526, involved in ibuprofen interactions).
The present study further found that the UA and COX-2 interaction profile detected upon molecular docking persisted in the MD simulations, even in the presence of temperature, pressure, water, and protein flexibility variations. In addition, the interactions of UA with amino acid residues adjacent to the COX-2 active site and the AA metabolism site, such as Tyr115, Ser119, Tyr122, Leu123, Asp125, and Pro528, might also intensify the COX-2 inhibitory potential of UA. On the basis of the referred facts: (1) UA might block the access of ligands to the COX-2 active site; (2) interactions with Arg120 and amino acid residues adjacent to the COX-2 active site might reduce arachidonic acid metabolization; and (3) interactions of COX-2 active site inhibitors with Arg120 and Glu524 have already been described, which demonstrates the relevance of these amino acid residues for the possible blocking of the COX-2 active site by UA ( Figure S5).
From a structural point of view, the NMDA receptor is a heterotetramer formed by 2 subunits, GluN1 and GluN2. These subunits are modulated by domains ATD, LBD, TMD, and CTD (Karakas and Furukawa, 2014). Activation of the NMDA receptor requires simultaneous binding of glutamate to GluN2 and glycine or d-serine to GluN1 through the interactions of the latter αamino and α-carboxyl groups with LBD regions. The LBD is formed by 3 transmembrane regions (M1, M2, and M3) and 2 segments (S1 and S2), which comprise the active site and are located in subdomains D1 and D2, respectively (Traynelis et al., 2010).
Through in silico tests was demonstrated that UA has the COX-2 enzyme and NMDA receptor as multi-targets. The interactions of UA with these two pharmacological targets suggest that there is inhibition of COX-2 activation, NMDA receptor and consequently reduction of the painful process. Compounds and multi-target drugs are currently a promising alternative for the treatment of complex and multifactorial pathologies. They present advantages over polypharmaceutical therapies such as: patient adherence to treatment, improved kinetics and therapeutic efficacy, increased therapeutic range, reduction of drug interactions, adverse and toxicological effects (Talevi, 2015;Nicolik et al., 2016). Because UA has exhibited this feature (multi-targets), it may be considered an advantage over other compounds described in the literature. Verano et al. (2013) has shown that UA 10 mg/kg (i.p) has an antinociceptive effect, so we chose this dose to test its effect orally and have confirmed the antinociceptive and anti-inflammatory effects of UA through inhibitions of the TRPV1 receptor and serotonergic synergism (5-HT); reduced IL-2, IL-6, interferon (IFN)-γ, TNF-α, reactive oxygen species (ROS), phospholipase A2 and NF-κβ release; reduced COX-2 and inducible nitric oxide synthase (iNOS) expression; (Kashyap et al., 2016) and favorable interactions for complexes formed with COX-1 and COX-2 (Magalhães et al., 2012). Zhang et al. (2013) demonstrated that UA can induce apoptosis of cancer cells by reducing COX-2 expression and Ma et al. (2014) demonstrated that UA reduced COX-2 expression in CCl 4 -treated animals. The results presented here evidenced that UA exerts peripheral antinociceptive effect by inhibiting COX-2 in carrageenan-induced paw edema test and analgesic central in the tail flick test.
Until now there are no studies performed in vivo or in silico to analyse the antinociceptive potential of compounds present in the aerial parts of B. verticillata. We suggest that the peripheral antinociceptive effect of this plant species is mainly due to actions of anti-inflammatory components. Possibly contributing to reducing the activity of the enzyme COX-2 and peripheral NMDA receptors, with consequent reductions in pain. In silico and in vivo studies allowed the selection and suggestion of UA as the main active compound in B. verticillata, as it exhibited desirable affinity parameters, stable interactions with COX-2 and NMDA receptor subunits GluN1a and GluN2B and presented peripheral and central analgesic effect. Thus, the UA is configured a promising molecule for the development of COX-2 inhibitors and NMDA receptor antagonists.

FUNDING
The present study was funded by the Maranhão Research Foundation (FAPEMA) and the National Council for Scientific and Technological Development (CNPq).